SCHEMBL13373241

SCHEMBL13373241

Cc1ccc(C)c(S(=O)(=O)N2CCN(C(=O)c3cccnc3C)CC2)c1

nearest known ligand 0.65

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.62
RAB9A P51151 2/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
ALDH1A1 P00352 2/20 0.62
GAA P10253 1/20 0.60
TDP1 Q9NUW8 2/20 0.56
HTT P42858 2/20 0.54
MEN1 O00255 1/20 0.53
KMT2A Q03164 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
MITF O75030 1/20 0.53
LMNA P02545 1/20 0.53
MAPK1 P28482 1/20 0.53
USP2 O75604 1/20 0.51
PKM P14618 1/20 0.50
ATM Q13315 1/20 0.50
POLB P06746 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12965957 0.86 HTT (0.50) L3MBTL1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL13373154 0.83 RAB9A (0.53) L3MBTL1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL28304921 0.80 ALDH1A1 (0.56) L3MBTL1SMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL13373156 0.80 TDP1 (0.58) L3MBTL1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL14777565 0.75 ALDH1A1 (0.57) L3MBTL1RAB9ASMN1; SMN2ALDH1A1GAA
SCHEMBL4164590 0.74 HTT (0.54) L3MBTL1RAB9ASMN1; SMN2ALDH1A1TDP1
SCHEMBL1429869 0.74 KMT2A (0.58) L3MBTL1SMN1; SMN2ALDH1A1GAAHTT
SCHEMBL24322677 0.74 PKM (0.65) L3MBTL1RAB9ASMN1; SMN2ALDH1A1TDP1
SCHEMBL19561856 0.73 KDM4E (0.57) RAB9ASMN1; SMN2ALDH1A1HTTMEN1
SCHEMBL29944077 0.73 KMT2A (0.53) L3MBTL1RAB9ASMN1; SMN2ALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8536183-B2 3-pyridylcarbonyl-piperazinylsulfonyl derivatives Convergence Pharmaceuticals Limited (GB) 2013-09-17 US disclosed
US-20120302746-A1 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES BESWICK PAUL JOHN (GB) 2012-11-29 US disclosed
US-8288388-B2 3-pyridylcarbonyl-piperazinylsulfonyl derivatives Convergence Pharmaceuticals Limited (GB) 2012-10-16 US disclosed
US-20100022555-A1 Novel Derivatives Convergence Pharmaceuticals Limited (GB) 2010-01-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100022555-A1 Novel Derivatives CACNB2, CACNA1B, CACNA1D L3MBTL1 4734/4885RAB9A 2604/4885SMN1; SMN2 809/4885
US-20120302746-A1 3-PYRIDYLCARBONYL-PIPERAZINYLSULFONYL DERIVATIVES CACNB2, CACNA1C, KCNJ2 L3MBTL1 4373/4885RAB9A 2717/4885SMN1; SMN2 463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.